RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
- Condition
- Adjustment Disorder
- Tested
- RE104 for Injection
- Sponsor
- Reunion Neuroscience Inc
Who can join
- Age
- 18 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Maximum age: 80 years
- Study condition: Adjustment Disorder
- Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF
- Is sufficiently ambulatory and capable of self care as necessary to complete study procedures
- Has normal cognitive function
- Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study
- If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant
- Is willing and able to comply with the conditions and requirements of the study
Exclusion 6
- Has a significant risk of suicide
- Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- Has active or a history of central nervous system malignancy
- Has other medically significant conditions rendering unsuitability for the study
- Has used or will need to use prohibited medications or therapies
- Has a known sensitivity or intolerance to study intervention or potential rescue medications
Where
32 sites, 32 recruiting
University of New Mexico, School of Medicine
Albuquerque, New Mexico, United States
University of Michigan
Ann Arbor, Michigan, United States
Emory University
Atlanta, Georgia, United States
University of Colorado
Aurora, Colorado, United States
Dell Medical School, University of Texas at Austin
Austin, Texas, United States
UAB, Psychiatry and Behavioral Neurology
Birmingham, Alabama, United States
and 26 more sites on ClinicalTrials.gov
Contact
-
Mark Pollack, Chief Medical Officer
1-888-880-REUN info@reunionneuro.com
Potential match only. Final eligibility is determined by the study team.